Kaeside Unachukwu
Psychiatric/Mental Health · Sugar Land, TXNPI 1306477906
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 311 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,626, 3.3 times the $1,109 reported in 2021. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $42.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$1K
- Alkermes, Inc.$991
- plus $3K from 13 others
What the payments were for
- Food & beverage$13,333100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 56 | $2,398 |
| Johnson & Johnson | 48 | $2,213 |
| Otsuka America Pharmaceutical, Inc. | 50 | $2,112 |
| Teva Pharmaceuticals USA, Inc. | 31 | $1,459 |
| AbbVie | 34 | $1,072 |
| Alkermes, Inc. | 13 | $991 |
| Axsome Therapeutics, Inc. | 8 | $639 |
| E.r. Squibb & Sons, L.L.C. | 11 | $562 |
| Neurocrine Biosciences, Inc. | 6 | $446 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $292 |
| Supernus Pharmaceuticals, Inc. | 11 | $260 |
| Lundbeck LLC | 14 | $202 |
| Vanda Pharmaceuticals Inc. | 2 | $145 |
| Noven Pharmaceuticals, Inc. | 1 | $133 |
| Sunovion Pharmaceuticals Inc. | 6 | $122 |
| Corium, LLC | 2 | $116 |
| Noven Therapeutics, LLC | 1 | $107 |
| Tris Pharma Inc | 3 | $55 |
| Adlon Therapeutics L.p. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,336
- CAPLYTA$1,542
- INVEGA SUSTENNA$1,123
- REXULTI$963
- ARISTADA$911
- INVEGA TRINZA$626
- VRAYLAR$467
- AUSTEDO$463
- Auvelity$380
- ABILIFY MAINTENA$373
- ABILIFY ASIMTUFII$373
- COBENFY$366
- INGREZZA$366
- Xelstrym$241
- Austedo XR$229
- ARISTADA INITIO$228
- UZEDY$225
- SPRAVATO$125
- Fanapt$125
- QELBREE$102
How this compares
$13,342 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 23 | $64,839 |
| CaplytaLumateperone Tosylate | 12 | $20,244 |
| Aripiprazole | 51 | $9,846 |
| Atomoxetine Hcl | 15 | $1,284 |
| Quetiapine Fumarate | 53 | $1,088 |
| Risperidone | 30 | $916 |
| Benztropine Mesylate | 37 | $800 |
| Lurasidone Hcl | 19 | $653 |
| Duloxetine Hcl | 42 | $568 |
| Buspirone Hcl | 39 | $546 |
| Gabapentin | 51 | $517 |
| Lamotrigine | 50 | $498 |
| Escitalopram Oxalate | 40 | $409 |
| Bupropion XlBupropion Hcl | 22 | $369 |
| Hydroxyzine Hcl | 12 | $347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $2,112 | $64,83923 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,398 | $20,24412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Sugar Land
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
- Jaime Nelson DensonAustin$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.